Fritextsökning
Artiklar per år
Innehållstyper
-
Business Sweden: “Companies have a lot to offer in data-driven precision medicine”
Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.
-
Larm om vaccinbrist efter utbrott av difteri i Västafrika
Ett allvarligt utbrott av difteri har drabbat Västafrika. Nu varnar Läkare utan gränser för brist på läkemedel och vaccin mot sjukdomen.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment line for cancer patients, and the company recently presented positive data from a phase II
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech.
-
Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”
The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.
-
Förlikning i babypuderskandal stoppas av domstol
Det amerikanska läkemedelsbolaget Johnson & Johnson har för en andra gång fått avslag av en domare om en konkursansökan för dotterbolaget LTL Management, mest känt som enheten bakom det omtalade babypudret som misstänkts ha orsakat cancer i en rad fall.
-
Rapid developments in AI – “All stakeholders are struggling to understand it”
Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, keeping up with developments is not easy.
-
Egetis lägger ned buddiskussionerna
Svenska läkemedelsutvecklaren Egetis Therapeutics har gått ut med att diskussionerna om ett potentiellt förvärv av företaget nu har lagts ner.
-
New report: Fewer PhDs in life sciences
A new report from Vinnova suggests that competency returns in the life science sector are declining.
-
Egetis bekräftar budsamtal
Den svenska läkemedelsutvecklaren Egetis Therapeutics för diskussioner om ett potentiellt bud på bolaget. Det bekräftar företaget i en kommentar till ihärdiga rykten på marknaden.
-
Så mycket väntas lecanemab sälja globalt
Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju miljarder dollar år 2030, enligt det japanska läkemedelsbolaget Eisai.
-
Företag i Kanada får börja tillverka kokain
Ett företag i den kanadensiska provinsen British Columbia har fått tillstånd att tillverka och sälja kokain på licens.
-
Individual DNA passport could result in fewer drug side effects
You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer side effects if the drug treatment is adapted to their genes.
-
"Unclear proposal from the EU Commission on how to solve the MDR challenges"
Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the availability of medical devices in the EU. Unfortunately, the fears have come true.